Insider Selling: Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Sells 3,000 Shares of Stock

Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Thomas David Hull III sold 3,000 shares of the stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $45.63, for a total transaction of $136,890.00. Following the transaction, the chief executive officer now directly owns 37,916 shares in the company, valued at $1,730,107.08. The trade was a 7.33 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Thomas David Hull III also recently made the following trade(s):

• On Friday, March 21st, Thomas David Hull III sold 213 shares of Kewaunee Scientific stock. The shares were sold at an average price of $48.53, for a total value of $10,336.89.
• On Friday, January 10th, Thomas David Hull III sold 1,368 shares of Kewaunee Scientific stock. The stock was sold at an average price of $60.08, for a total value of $82,189.44.
• On Thursday, December 26th, Thomas David Hull III sold 2,000 shares of Kewaunee Scientific stock. The shares were sold at an average price of $63.01, for a total value of $126,020.00.

Kewaunee Scientific Price Performance

KEQU opened at $40.00 on Thursday. The company has a quick ratio of 2.13, a current ratio of 2.64 and a debt-to-equity ratio of 0.45. The company’s 50-day moving average price is $56.58 and its 200 day moving average price is $47.50. Kewaunee Scientific Co. has a fifty-two week low of $30.82 and a fifty-two week high of $71.33. The firm has a market cap of $114.20 million, a price-to-earnings ratio of 6.34 and a beta of 0.71.

Kewaunee Scientific (NASDAQ:KEQU) last announced its quarterly earnings results on Wednesday, March 12th. The technology company reported $1.09 earnings per share (EPS) for the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%. The business had revenue of $67.17 million for the quarter.

Hedge Funds Weigh In On Kewaunee Scientific

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE increased its holdings in shares of Kewaunee Scientific by 2,605.9% in the 4th quarter. Bank of America Corp DE now owns 460 shares of the technology company’s stock worth $28,000 after acquiring an additional 443 shares during the period. JPMorgan Chase & Co. grew its position in Kewaunee Scientific by 18,000.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company’s stock worth $30,000 after purchasing an additional 900 shares during the last quarter. IFP Advisors Inc acquired a new stake in shares of Kewaunee Scientific in the fourth quarter valued at approximately $36,000. Morgan Dempsey Capital Management LLC bought a new stake in shares of Kewaunee Scientific during the fourth quarter valued at approximately $106,000. Finally, Barclays PLC acquired a new position in shares of Kewaunee Scientific during the third quarter worth approximately $121,000. Institutional investors and hedge funds own 32.69% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Kewaunee Scientific from a “buy” rating to a “hold” rating in a research note on Friday, March 14th.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.